The goal of the study is to demonstrate that SINUclean DM® spray, added to the standard (amoxicillin/clavulanate) therapy of the acute episode of sinusitis (acute, subacute or chronic), is safe ad capable to determine the resolution of the symptoms in a shorter time in comparison with the standard therapy without co-adjuvant, or with simple saline lavage.

The randomized subject with diagnosis of acute episode of sinusitis with symptoms and mucus in the paranasal sinuses, will treat his/her condition with background amoxicillin/clavulanate and with inhalation of Sinuclean or Saline, while the control group will not use any spray for symptom relief. Anti-histaminic, steroidal anti-inflammatory drugs are forbidden. The patient is requested to evaluate his state of symptoms by recording in a diary

• the pain or feeling of facial oppression;

• nasal dripping anterior or posterior;

• nasal congestion. SCALE 0 = no symptom

  1. = mild symptom: clearly perceptible, but easily tolerated
  2. = moderate symptom: clear awareness of the symptom, that is annoying but tolerable
  3. = severe: symptom very annoying, difficult to tolerate, interfering with the ordinary life Four measures per day (2 for administration of the therapy - before/after) of which the median will be used; plus an evening measure "retrospective" of the past 12 hours.

If possible it will be assessed the status of paranasal sinuses before and after the treatment with a CT scan.

The treatment intervals is the week. After baseline and start of treatment, are planned two control visit. The subject will complete the study at the first control visit without symptoms. After the second visit, if the symptoms are still present, the subject will complete as a "treatment-failure".

Inclusion Criteria:

• Male or female sex.
• Age > 18 years old.
• Diagnosis of acute episode of sinusitis (in an acute, subacute or chronic background), confirmed with a CT scan image.
• Presence of mucus in para-nasal sinuses.
• Symptoms of facial pain associated to the congestion of the mucosa of the paranasal sinuses for at least three days.
• Written informed consent.
• Expressed intention of compliance with the study requirements.

Exclusion Criteria:

• In case of female subject: ongoing pregnancy or lactating; or condition of fecundity without abstinence.
• Assumption, during the study, of drugs that can interfere with the evaluation of the investigational drug (see Section "Concomitant Therapy")
• Possible necessity of treatment, during the study, with drugs that are not allowed (see section "Concomitant Therapy").
• Clinical conditions (systemic pathologies or other) that can interfere with the assessment of the safety and efficacy of the investigational drug, in example: viral or allergic rhinitis with active secretive symptomatology, presence of visible nasal polyps, diagnosis of immobile cilia syndrome, diseases determining immunodeficiency cystic fibrosis immunocompromission renal insufficiency, dialysis, pathology of other apparatus that, in the opinion of the investigator, necessity of a supplementary antibiotic therapy,due to other pathologies, besides the one standard of the sinusitis.
• Psychical conditions not compatible with the participation to the clinical trial.
• Alcohol abuse or other dependencies on stupefacents
• Smoking during the period of the study
• History of intolerance or allergy to the components of SINUclean DM®
• Surgical or medical intervention that can jeopardize the complete performance of the trial, in the 4 wks preceding the administration of the informed consent
• Planning of a surgical or medical intervention that can jeopardize the completion of the trial
• Participation to other clinical trials, ongoing or terminated since less than 30 days before the beginning of the present experiment.
• Preceding randomization in this trial.
• Be component of the investigators' staff or be a relative of a member of the staff.

The period in which Adverse Events were collected was the period of observation of the patient between the Start and the End of the therapy: two weeks maximum.

A 0 frequency means that no events were reported or observed in all the patients of the group considered.

Clinical diagnosis could not be confirmed before treatment start due to logistics problems to make cranial MRI in due time.